BCTXW
BriaCell Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · CA
$0.00
−0.00%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 106.8K | 117.9K | 147.9K | 114.0K | 20.5K |
| Gross Profit | (106.8K) | (117.9K) | (147.9K) | (114.0K) | (20.5K) |
| Operating Expenses | |||||
| R&D Expense | 31.5M | 29.2M | 29.5M | 37.5K | 15.3M |
| SG&A Expense | 7.4M | 6.8M | 8.1M | 9.2K | 7.9M |
| General & Admin Expense | 3.3M | 6.8M | — | 8.5K | 7.9M |
| Selling & Marketing Expense | — | — | — | 685.30 | — |
| Other Expenses | — | — | — | (685.00) | (763.00) |
| Total Operating Expenses | 38.8M | 36.1M | 37.6M | 46.0K | 23.3M |
| Cost and Expenses | 42.1M | 35.6M | 37.7M | 46.0K | 23.3M |
| Operating Income (EBIT) | (42.1M) | (35.6M) | (37.7M) | (46.0K) | (23.3M) |
| Non-Operating | |||||
| Interest Income | 603.2K | 626.0K | 166.4K | 391.5K | 891.2K |
| Interest Expense | 29.6K | — | 51.3K | — | — |
| Net Interest Income | 573.6K | 626.0K | 115.1K | 391.5K | — |
| Other Non-Op Income/Expense | 836.7K | 720.1K | 899.7K | 39.2K | 3.0M |
| Non-Operating Income (excl Interest) | (413.4K) | — | (951.0K) | — | 4.0M |
| EBT (Pre-Tax Income) | (41.3M) | (34.9M) | (36.8M) | (6.8K) | (20.3M) |
| Income Tax Expense | — | — | — | — | (153.0K) |
| Bottom Line | |||||
| Net Income | (40.8M) | (34.9M) | (36.5M) | (6.6K) | (20.3M) |
| Earnings from Cont. Ops | (41.3M) | (34.9M) | (36.8M) | (6.8K) | (27.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (37.6M) | (34.9M) | (36.5M) | (6.5M) | (26.8K) |
| Per Share | |||||
| Basic EPS | ($10.34) | ($6.97) | ($86.25) | ($4.28) | ($19.79) |
| Diluted EPS | ($10.34) | ($6.97) | ($86.25) | ($4.28) | ($19.79) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 8.7M | 5.0M | 423114 | 1.1M | 1.0M |
| Diluted Shares Outstanding | 8.7M | 5.0M | 423114 | 1.1M | 1.0M |
| Profitability Metrics | |||||
| EBITDA | (41.6M) | (35.5M) | (36.6M) | (45.9K) | (27.2M) |
| D&A | 139.8K | 117.9K | 147.9K | 115.84 | 15.3K |
| EBIT | (41.7M) | (35.6M) | (36.8M) | (46.0K) | (27.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026